Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study
Main finding · MACEResult — go to the resultAdjusted hazard ratio 2.03 95% CI 1.60–2.57Authors' conclusion
UTI in patients with T2DM post-SLGT2i therapy is associated with an increased risk of MACE for up to 30 months.
Study context
- Population
- T2D patients treated with SGLT2i, January 2016–January 2019
- Participants
- 8,862 patients
- Exposure
- Urinary tract infection (UTI) vs no UTI after SGLT2i treatment
- UTIn = 550
- Outcome
- MACE: composite of nonfatal MI, nonfatal stroke, cardiac death, all-cause death or HF hospitalization
- Follow-up
- Up to 30 months
Methodological detailsmulticenter, observational, multivariate-adjusted
- Multicenter
- Observational
- Multivariate-adjusted
Main finding
MACE
Adjusted hazard ratio
2.03
95% CI 1.60–2.57
P < 0.0001
UTIvs Without UTI
aHR 2.03 (95% CI 1.60–2.57); P < 0.0001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| HF hospitalization · up to 30 months | 1.66 (1.32–2.09) | P < 0.0001 | |
| All-cause mortality · up to 30 months | 2.67 (2.10–3.40) | P < 0.0001 | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
Cardiovascular Outcomes of Patients With Type 2 Diabetes With Urinary Tract Infection Post Sodium-Glucose Cotransporter 2 Inhibitors Treatment: A Multicenter Observational Study. Endocr Pract. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →